Skip to main content
padlock icon - secure page this page is secure

Poly(L-lactic acid)/Hydroxyapatite Nanocylinders as Nanofibrous Structure for Bone Tissue Engineering Scaffolds

Buy Article:

$106.67 + tax (Refund Policy)

Poly (L-lactic acid) (PLLA), a biodegradable and biocompatible polyester, has been used as material of for tissue engineered scaffold and regenerative medicine. In this study, hydroxyapatite (HAp) and PLLA composite was electrospun. PLLA fibers were treated with an amino groups containing base in order to fabricate amino groups modified polymeric microcylinders. Simvastatin was loaded into the PLLA/HAp microcylinders. Our study focuses on the incorporation HAp and Simvastatin into the fibrous and cylindrical structure, its effects on the loading and release of simvastatin, and biological responses to osteoblast cells. The aspect ratio of microcylinders was tunable by varying the aminolysis treatment time and density of the base. The effects of the PLLA/HAp composites on osteoblast cell proliferation were evaluated. The PLLA/HAp may interact with osteoblast and obtain desired effects that were stimulating osteoblast function and restraining the osteoclast function for bone tissue regeneration. The potential of the developed composite microcylinders could be a promising way to fabricate the microfibrous structural scaffold that accelerates cell proliferation and functions for bone tissue engineering.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: BONE TISSUE ENGINEERING; HYDROXYAPATITE (HAP); MICROCYLINDER; POLY(L-LACTIC ACID) (PLLA); SIMVASTATIN

Document Type: Research Article

Publication date: March 1, 2013

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more